November 10, 2015 — A federal judge in California has shot down state law failure-to-warn claims involving pancreatic side effects of several diabetes drugs, Law360 reports.
In an order (PDF) granting defendants’ motion for summary judgement, U.S. District Judge Anthony J. Battaglia found that the FDA would have rejected warning labels about pancreatic cancer even if drug-makers had wanted to add them.
The agency issued a Safety Communication about the study in March 2013, but decided that a new warning label wasn’t needed.
Earlier this year, European health officials said the study “had a number of methodological limitations and potential sources of bias.” Soon afterward, the FDA closed its investigation.
That decision essentially preempts any failure-to-warn claims under state law, according to Judge Battaglia. Therefore, drug-makers Merck & Co., Eli Lilly & Co., Novo Nordisk, and Amylin Pharmaceuticals had no duty to warn patients or doctors about the potential risk.
Plaintiffs argued that lawsuits should not be preempted because the FDA was inadequately evaluating evidence and failing to act.
About 750 lawsuits involving diabetes drugs like Januvia (sitagliptin), Onglyza (saxagliptin),and Nesina (alogliptin) have been centralized in California district court since August 2013. Another 44 cases are pending in other federal courts around the nation.
Need a Januvia Lawyer in Texas?
Collen A. Clark is a true advocate for his clients and is passionate about helping Texans that have been injured or wronged.
Collen’s amazing success in the courtroom and well known dedication to his clients has earned him the recognition of his peers as one of The Top Trial Lawyers in Texas.”
The Clark Firm has assembled a team of trial lawyers with more than 100 years experience, participation in over 600 jury trials and $260 million in verdicts and/or settlements. Please use the form below to contact our Texas Januvia lawyers for a free lawsuit review.